The Jakarta Post
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsSome antibody drugs for COVID-19 may not be effective on Omicron
The findings by Yoshihiro Kawaoka, a professor of virology at the University of Tokyo's Institute of Medical Science, and others were published in the New England Journal of Medicine on Wednesday.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
An illustration picture taken in London on December 2, 2021 shows four syringes and a screen displaying the word 'Omicron', the name of the new covid 19 variant, and an illustration of the virus. (AFP/Justin Thallis)
S
ome antibody medicines including Ronapreve may not be effective against the highly-mutated Omicron variant of the coronavirus, according to researchers at Japanese and US institutes.
The findings by Yoshihiro Kawaoka, a professor of virology at the University of Tokyo's Institute of Medical Science, and others were published in the New England Journal of Medicine on Wednesday.
The researchers examined the neutralizing ability of approved and investigational therapeutic antibodies against Omicron and other variants of concern.
The outcomes of their study, in which medicines were given to cultured cells of people exposed to the virus, showed that a Ronapreve antibody cocktail retained activity against Beta and Gamma variants but lost inhibitory capability against Omicron.
In the meantime, the results suggested the oral drug molnupiravir and the IV drug remdesivir are likely effective against the highly-contagious variant.
Sotrovimab, a monoclonal antibody drug, exhibited some efficacy against Omicron but it was lower compared with other variants including Delta.
The Japanese Ministry of Health, Labor and Welfare decided in December not to recommend the administration of Ronapreve on patients who are potentially infected with the Omicron variant.
More from The Weekender
Farewell, good breast
A cancer diagnosis brings more than the fear of illness. It raises difficult questions about how to protect those we love while revealing unexpected reserves of tenderness and resilience.
Siapa Anda? Mengapa Anda?
What begins as a small grammatical curiosity becomes a larger question about language, culture and the way we understand ourselves in relation to others - and, ultimately, about what we risk losing in a world increasingly impatient with reflection, ambiguity and the humanities.
A passport to the kingdom of the sick
A breast cancer diagnosis, a journey to the kingdom of the sick and a determination to describe what lies there without metaphor, euphemism or the word “fight.”
